Table 4.
Summary of drug-drug interaction randomized controlled trials
| Medication Class | MDMA RCTsa | Psilocybin RCTsa |
|---|---|---|
|
| ||
| Adrenergic Agents | carvedilol | ergotamine |
| pindolol | ||
| clonidine ER | ||
| doxazosin XL | ||
| Antipsychotics | haloperidol | chlorpromazine |
| haloperidol | ||
| risperidone | ||
| Anxiolytics | buspirone | |
| MAOIs | ||
| Mood Stabilizers | ||
| NDRIs | bupropion XR | |
| NMDAR Antagonists | memantine | |
| Psychostimulants | methylphenidate | |
| SSRIs | citalopram | escitalopram |
| fluoxetine | ||
| paroxetine | ||
| SNRIs | duloxetine | |
| reboxetine | ||
MAOI monoamine oxidase inhibitor, NDRI norepinephrine-dopamine reuptake inhibitor, NMDAR N-methyl-D-aspartate receptor, RCT randomized controlled trial, SNRI serotonin-norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor
a
See Table 5 for randomized controlled trial citations, study designs, and sample description
Not included: MDMA/ecstasy co-ingestion from cross-sectional studies (Copeland et al. 2006; Cohen et al. 2021) or epidemiologic data from online “trip reports” (Nayak et al. 2021)